Aura Biosciences (AURA) Stock Analysis

What Aura Biosciences does

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Key metrics

ETFs linked to AURA

Broad-market and Healthcare sector ETFs an investor holding Aura Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AURA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Aura Biosciences?

Aura Biosciences trades under the ticker AURA on NASDAQ.

Which exchange is AURA listed on?

AURA is listed on NASDAQ.

What sector does Aura Biosciences operate in?

Aura Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AURA in a portfolio?

PortView shows AURA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.